Skip to main content

Table 2 Base case results: individual- and population-level antiretroviral health benefits in a setting with inadequate treatment availability

From: Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability

 

Treated individuals only

Treated and untreated individuals†

Strategy*

Life expectancy (Years)

Mean time on treatment (Years)

Mean number initiating treatment annually

Life expectancy (Years)

Total life-years (Years)

Mean annual treatment coverage‡ (%)

Status Quo

8.8

7.4

5,880

3.6

540,000

24.4

Alternative

8.1

6.3

6,980

3.7

555,000

29.0

  1. *In the Status Quo, antiretroviral therapy (ART) is never discontinued. In the Alternative strategy, ART is discontinued when second-line ART failure is observed. In the base case, ART failure is defined as a 50% decrease in peak on-treatment CD4 count, CD4 count <100 cells/μL, CD4 count below pre-ART nadir, or a WHO stage III/IV event, excluding tuberculosis and severe bacterial infections [6]. On average, individuals who received no treatment lived approximately 1.9 years.
  2. †Results are presented for a 5-year analytic time horizon for a cohort of 30,000 newly detected HIV-infected individuals entering care annually.
  3. ‡Treatment coverage is defined as the ratio of the number receiving treatment annually to the number qualifying for treatment annually.
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us